1834 Investment Advisors Co. Purchases 166 Shares of Danaher Co. (NYSE:DHR)

1834 Investment Advisors Co. increased its position in shares of Danaher Co. (NYSE:DHR) by 10.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,707 shares of the conglomerate’s stock after acquiring an additional 166 shares during the period. 1834 Investment Advisors Co.’s holdings in Danaher were worth $475,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Financial Security Advisor Inc. increased its holdings in shares of Danaher by 26.2% in the third quarter. Financial Security Advisor Inc. now owns 3,302 shares of the conglomerate’s stock worth $919,000 after purchasing an additional 685 shares during the period. Catalina Capital Group LLC grew its position in Danaher by 11.3% during the third quarter. Catalina Capital Group LLC now owns 3,127 shares of the conglomerate’s stock worth $869,000 after buying an additional 318 shares in the last quarter. Northstar Asset Management Inc. increased its stake in Danaher by 0.6% in the 3rd quarter. Northstar Asset Management Inc. now owns 34,654 shares of the conglomerate’s stock worth $9,635,000 after acquiring an additional 190 shares during the last quarter. Marks Group Wealth Management Inc boosted its position in shares of Danaher by 5.0% during the 3rd quarter. Marks Group Wealth Management Inc now owns 4,660 shares of the conglomerate’s stock valued at $1,296,000 after acquiring an additional 223 shares during the last quarter. Finally, Balentine LLC purchased a new position in shares of Danaher during the third quarter worth about $420,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Trading Down 0.9 %

DHR opened at $247.81 on Thursday. Danaher Co. has a one year low of $192.35 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The business has a 50 day simple moving average of $265.79 and a two-hundred day simple moving average of $260.75. The firm has a market capitalization of $178.99 billion, a price-to-earnings ratio of 47.29, a PEG ratio of 4.55 and a beta of 0.85.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.02 earnings per share. Analysts predict that Danaher Co. will post 7.51 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is currently 20.61%.

Analysts Set New Price Targets

DHR has been the subject of several research analyst reports. Bank of America lifted their target price on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Leerink Partners upped their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. TD Cowen raised their price target on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Wells Fargo & Company assumed coverage on Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective for the company. Finally, The Goldman Sachs Group raised their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $287.16.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.90% of the stock is currently owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.